Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì
  #1  
Ñòàðûé 02.06.2016, 08:12
Iuniadoctor Iuniadoctor âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 24.10.2014
Ãîðîä: Êàçàõñòàí
Ñîîáùåíèé: 72
Ñêàçàë(à) ñïàñèáî: 23
Ïîáëàãîäàðèëè 2 ðàç(à) çà 2 ñîîáùåíèé
Iuniadoctor ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
ãðàíèöû ðåôåðåíñà äëÿ òåñòîñòåðîíà

Ïèøåò äîêòîð ýíäîêðèíîëîã. Ïðîøó ïðîùåíèÿ çàðàíåå çà, íàâåðíîå, ïðèìèòèâíûé è ãëóïîâàòûé âîïðîñ, íî óæ êîëè âîçíèê, äóìàþ, ëó÷øå çàäàì, ÷åì áóäó ìó÷èòüñÿ.
Ïðè îöåíêå óðîâíÿ òåñòîñòåðîíà ïðèâûêëà ïîëüçîâàòüñÿ åäèíèöàìè èçìåðåíèÿ â íìîëü\ë( êàê è â áîëüøèíñòâå ìåä ëèòåðàòóðû, ðàçëè÷íûõ ðåêîìåíäàöèÿõ, êîíñåíñóñàõ è ò.ä.) Äàæå åñëè ðåçóëüòàò â íã\ìë, òî ïåðåâîæó â íìîëü\ë, êàê-òî ïðèâû÷íåå. Ïîñëåäíèé ðàç îäíà íàøà àâòîðèòåòíàÿ ëàáîðàòîðèÿ íà÷àëà âûäàâàòü ðåôåðåíñíûå çíà÷åíèÿ â íìîëü\ë, íî ñàìè ãðàíèöû ðåôåðåíñà äðóãèå: äëÿ ìóæ÷èíû âçðîñëîãî - îò 5.0 äî 19.0 íìîëü\ë. Ïðè óðîâíå òåñòîñòåðîíà 12.5 íìîëü\ë, â äàííîì ñëó÷àå ýòî íå òå 12.5 íìîëü\ë, êîòîðûå ÿâëÿþòñÿ íèæíåé ãðàíèöåé íîðìû, à î÷åíü äàæå «íîðìà»? ïðàâèëüíî? Àíàëèçàòîð Båckman Cîulter Access( CØA). Ïðîñòî ïàöèåíò äî ýòîãî èñïîëüçîâàë äðóãóþ ëàáîðàòîðèþ. È óðîâåíü Ò. áûë äîâîëüíî ñòàáèëüíûé ñ òå÷åíèåì âðåìåíè, êàê ðàç öèôðà ïî÷òè òà æå( íèæíÿÿ ãðàíèöà íîðìû), òîëüêî ðåôåðåíñ áûë äðóãîé( êàê ðàç îò 12.0 íìîëü\ë). À òóò âäðóã ïîäñêî÷èë â 2 ðàçà áåç îñîáûõ ïðè÷èí( ýòî òî÷íî).
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 04.06.2016, 11:01
Drontiy Drontiy âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 06.10.2014
Ãîðîä: Ðîñòîâ-íà-Äîíó
Ñîîáùåíèé: 497
Ñêàçàë(à) ñïàñèáî: 12
Ïîáëàãîäàðèëè 267 ðàç(à) çà 241 ñîîáùåíèé
Drontiy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDrontiy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDrontiy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDrontiy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDrontiy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDrontiy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âîò íîðìû èç Denise D.Wilson.
Íàæìèòå íà èçîáðàæåíèå äëÿ óâåëè÷åíèÿ
Íàçâàíèå: òåñòîñòåðîí.png
Ïðîñìîòðîâ: 44
Ðàçìåð:	28.0 Êá
ID:	104461
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 04.06.2016, 13:04
AlexT AlexT âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 12.06.2003
Ãîðîä: Êðèâîé Ðîã
Ñîîáùåíèé: 861
Ïîáëàãîäàðèëè 64 ðàç(à) çà 61 ñîîáùåíèé
AlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Iuniadoctor Ïîñìîòðåòü ñîîáùåíèå
Ïèøåò äîêòîð ýíäîêðèíîëîã. Ïðîøó ïðîùåíèÿ çàðàíåå çà, íàâåðíîå, ïðèìèòèâíûé è ãëóïîâàòûé âîïðîñ, íî óæ êîëè âîçíèê, äóìàþ, ëó÷øå çàäàì, ÷åì áóäó ìó÷èòüñÿ.
Ïðè îöåíêå óðîâíÿ òåñòîñòåðîíà ïðèâûêëà ïîëüçîâàòüñÿ åäèíèöàìè èçìåðåíèÿ â íìîëü\ë( êàê è â áîëüøèíñòâå ìåä ëèòåðàòóðû, ðàçëè÷íûõ ðåêîìåíäàöèÿõ, êîíñåíñóñàõ è ò.ä.) Äàæå åñëè ðåçóëüòàò â íã\ìë, òî ïåðåâîæó â íìîëü\ë, êàê-òî ïðèâû÷íåå. Ïîñëåäíèé ðàç îäíà íàøà àâòîðèòåòíàÿ ëàáîðàòîðèÿ íà÷àëà âûäàâàòü ðåôåðåíñíûå çíà÷åíèÿ â íìîëü\ë, íî ñàìè ãðàíèöû ðåôåðåíñà äðóãèå: äëÿ ìóæ÷èíû âçðîñëîãî - îò 5.0 äî 19.0 íìîëü\ë. Ïðè óðîâíå òåñòîñòåðîíà 12.5 íìîëü\ë, â äàííîì ñëó÷àå ýòî íå òå 12.5 íìîëü\ë, êîòîðûå ÿâëÿþòñÿ íèæíåé ãðàíèöåé íîðìû, à î÷åíü äàæå «íîðìà»? ïðàâèëüíî? Àíàëèçàòîð Båckman Cîulter Access( CØA). Ïðîñòî ïàöèåíò äî ýòîãî èñïîëüçîâàë äðóãóþ ëàáîðàòîðèþ. È óðîâåíü Ò. áûë äîâîëüíî ñòàáèëüíûé ñ òå÷åíèåì âðåìåíè, êàê ðàç öèôðà ïî÷òè òà æå( íèæíÿÿ ãðàíèöà íîðìû), òîëüêî ðåôåðåíñ áûë äðóãîé( êàê ðàç îò 12.0 íìîëü\ë). À òóò âäðóã ïîäñêî÷èë â 2 ðàçà áåç îñîáûõ ïðè÷èí( ýòî òî÷íî).
Äëÿ Access ðåôåðåíòíûå âåëè÷èíû:
[Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì]

Òàê öèôðà îñòàëàñü òàêàÿ æå (îêîëî 12) èëè âûðîñëà â 2 ðàçà? Èëè òîëüêî ðåô ïðåäåëû ïîìåíÿëèñü?
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 04.06.2016, 13:19
Samitin Samitin âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 27.08.2009
Ãîðîä: Ñàðàòîâ
Ñîîáùåíèé: 2,224
Ñêàçàë(à) ñïàñèáî: 8
Ïîáëàãîäàðèëè 765 ðàç(à) çà 691 ñîîáùåíèé
Samitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âîïðîñ, ïîëàãàþ, íå â ðåôåðåíòíûõ âåëè÷èíàõ êîíêðåòíîé òåñò-ñèñòåìû, êîòîðûå, ïðàâäà, íå î÷åíü äîáðîñîâåñòíî ïåðåïèñàíû ëàáîðàòîðèåé íà áëàíê èç èíñòðóêöèè (à âäðóã ëàáîðàòîðèÿ ñàìà ðåôåðåíñ óñòàíàâëèâàëà, êàê è ïîëîæåíî?!), à â òîì, êàê îíûé ðåôåðåíñ ñîîòíåñòè ñ ðåôåðåíñàìè äðóãèõ íàáîðîâ è ãàéäàìè ïî ãèïîãîíàäèçìó... Ñîîòíåñòè - êàòàñòðîôè÷åñêè òðóäíî: ñì, íàïðèìåð, ñîîòâåòñâóþùèé ðàçäåë èç The Laboratory Diagnosis of Testosterone Deficiency by American Urological Association, 2013 ([Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]).

Ïîýòîìó ñ êëèíè÷åñêèõ ïîçèöèé ðèñêíó ïðåäëîæèòü: íå ìåíÿòü èñïîëüçóåìóþ ó êîíêðåòíîãî ïàöèåíòà òåñò-ñèñòåìó, åñëè òîëüêî ìåíÿåì íå íà òó, êîòîðàÿ ïîêàçàëà ñåáÿ áëèæå ê ðåôåðåíòíûì ìåòîäàì.
Èññëåäîâàíèå, âêëþ÷àâøåå òåñò-ñèñòåìó, î êîòîðîé èäåò ðå÷ü: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ].
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 06.06.2016, 14:32
Iuniadoctor Iuniadoctor âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 24.10.2014
Ãîðîä: Êàçàõñòàí
Ñîîáùåíèé: 72
Ñêàçàë(à) ñïàñèáî: 23
Ïîáëàãîäàðèëè 2 ðàç(à) çà 2 ñîîáùåíèé
Iuniadoctor ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
Ñïàñèáî, äîêòîð Ñàìèòèí, Âû ñîâåðøåííî ïðàâèëüíî ìåíÿ ïîíÿëè. ß äåéñòâèòåëüíî èìåëà â âèäó, êàê ñîîòíîñèòü âûøåèçëîæåííûå äàííûå ñ ðàçëè÷íûìè ðåêîìåíäàöèÿìè, â ÷àñòíîñòè, è ïî âîçðàñòíîìó, è ïî ïîäðîñòêîâîìó ãèïîãîíàäèçìó è ò.ï. Òàê è ñäåëàþ. Ê ñîæàëåíèþ, âûáîð ó íàñ íåáîëüøîé, íî ýòî ñîîîâñåì î äðóãîì.
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 06.06.2016, 14:44
Iuniadoctor Iuniadoctor âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 24.10.2014
Ãîðîä: Êàçàõñòàí
Ñîîáùåíèé: 72
Ñêàçàë(à) ñïàñèáî: 23
Ïîáëàãîäàðèëè 2 ðàç(à) çà 2 ñîîáùåíèé
Iuniadoctor ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
îòâåò äëÿ AlexT

Äà, ñàìà öèôðà ïî÷òè òà æå, ( ïî ïàìÿòè), ÷òî-òî îêîëî 12.2 - 12.6 íìîëü\ë. Ïðàâäà. âåðõíèé óðîâåíü â íàøåé ëàáîðàòîðèè áûë ÷òî-òî îêîëî 19.0 íìîëü\ë( òî÷íûå äàííûå íà ðàáîòå). Âûõîäèò, ÷òî è ïðè òàêèõ ðåôåðåíòíûõ çíà÷åíèÿõ ìû äîëæíû ðóêîâîäñòâîâàòüñÿ òåì, ÷òî æåëàòåëüíûé óðîâåíü äëÿ âçðîñëîãî ìóæ÷èíû - íå íèæå 13 íìîëü\ë. Æäó ïàöèåíòà ñ âòîðè÷íûì ãèïîãîíàäèçìîì( ïîñëå îïåðàöèè), ïðè íàçíà÷åíèè ÇÃÒ áóäó îðèåíòèðîâàòüñÿ íà ìèðîâûå ñòàíäàðòû( 12 -13 íìîëü\ë),òàê ÿ ïîíÿëà.
Îòâåòèòü ñ öèòèðîâàíèåì
  #7  
Ñòàðûé 06.06.2016, 18:08
Samitin Samitin âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 27.08.2009
Ãîðîä: Ñàðàòîâ
Ñîîáùåíèé: 2,224
Ñêàçàë(à) ñïàñèáî: 8
Ïîáëàãîäàðèëè 765 ðàç(à) çà 691 ñîîáùåíèé
Samitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Äà, ïîëàãàþ, âíå çàâèñèìîñòè îò ðåôåðåíñà ïðèä¸òñÿ îðèåíòèðîâàòüñÿ íà óêàçàííûé â ðóêîâîäñòâàõ îòðåçíîé óðîâåíü (õîòÿ èñïîëüçîâàííàÿ ñèñòåìà è ïðàâäà íåõîðîøà, à èç áîëåå äîñòóïíûõ, êàê óêàçûâàåò óâàæàåìûé AlexT, ñòîèò îðèåíòèðîâàòüñÿ íà èììóíîõåìèëþìèíåñöåíòíûå ñèñòåìû, áóäå òàêîâûå íàéäóòñÿ)... Òîëüêî ïîñìîòðèòå åù¸ ðàç â óðîëîãè÷åñêîì äîêóìåíòå ïî ññûëêå âûøå — òàì õîðîøî ñóììèðîâàíû ðàçíûå âçãëÿäû íà ýòî ñàìîå ãðàíè÷íîå çíà÷åíèå.
Îòâåòèòü ñ öèòèðîâàíèåì
  #8  
Ñòàðûé 06.06.2016, 23:06
AlexT AlexT âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 12.06.2003
Ãîðîä: Êðèâîé Ðîã
Ñîîáùåíèé: 861
Ïîáëàãîäàðèëè 64 ðàç(à) çà 61 ñîîáùåíèé
AlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íå íóæíî ñìåøèâàòü ðåôåðåíòíûå âåëè÷èíû , ïîëó÷åííûå êàê 95% ÄÈ äëÿ ðàñïðåäåëåíèÿ òåñòîñòåðîíà ðåôåðåíòíîé ïîïóëÿöèè (êàê â ýòîé òåñò-ñèñòåìå) è êëèíè÷åñêèå ïîðîãè ïðèíÿòèÿ ðåøåíèé êàê â ðóêîâîäñòâàõ, îíè ìîãóò íå ñîâïàäàòü, è ðåøåíèå íèçêèé ýòî óðîâåíü èëè íåò íå îáÿçàòåëüíî îñíîâàíî íà áèîëîãè÷åñêèõ 95% ÄÈ ðåôåðåíòíûõ äèàíàçîíàõ:

Öèòàòà:
There is no consensus among endocrinologists, urologists and clinical pathologists as to what defines a “low” T level. Published normal assay ranges for serum T are mostly based on studies in older men (>65 years old) and were not specifically designed to establish normal assay ranges in men with normal sexual and reproductive function. It is clear that T level correlates with overall health status and normal sexual function. To best serve our patients, it is our belief that the normal ranges should be based on apredefined, healthy index population representing the demographic structure of the United States. The Endocrine Society recommends that total low T be defined using local, normal assay ranges in the presence of characteristic signs or symptoms diagnostic of hypogonadism.2 The Food and Drug Administration (FDA) uses a cut-off value of 300 ng/dL to define hypogonadism for clinical trial development and enrollment. Meanwhile, a consensus statement from the International Society of Andrology (ISA), the International Society for Study of the Aging Male (ISSAM), the European
Association of Urology (EAU), the European Association of Andrology (EAA) and the American Society of Andrology (ASA) recommended that TT levels above 350 ng/dL do not require treatment, and levels below 230 ng/dL (with symptoms) may require T replacement therapy.3 For levels between
230-350 ng/dL, the recommendation is to repeat the TT with SHBG for calculation of FT or direct measurement of FT by equilibrium dialysis.3 Similarly, it has been previously recommended that men with TT<200 ng/dL be treated as hypogonadal, those with TT>400 ng/dL be considered normal and those with TT 200-400 ng/dL be treated based on their clinical presentation if symptomatic
Îòâåòèòü ñ öèòèðîâàíèåì
  #9  
Ñòàðûé 06.06.2016, 23:15
AlexT AlexT âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 12.06.2003
Ãîðîä: Êðèâîé Ðîã
Ñîîáùåíèé: 861
Ïîáëàãîäàðèëè 64 ðàç(à) çà 61 ñîîáùåíèé
AlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Samitin Ïîñìîòðåòü ñîîáùåíèå
à èç áîëåå äîñòóïíûõ, êàê óêàçûâàåò óâàæàåìûé AlexT, ñòîèò îðèåíòèðîâàòüñÿ íà èììóíîõåìèëþìèíåñöåíòíûå ñèñòåìû, áóäå òàêîâûå íàéäóòñÿ)...
Òåñò-ñèñòåìû, íåïëîõî çàðåêîìåíäîâàâøèå ñåáÿ ó ìóæ÷èí ïî äàííûì èññëåäîâàíèé - Roshe Elecsys Tåñòîñòåðîí 2 ïîêîëåíèÿ (äëÿ ïðèáîðîâ Elecsys èëè Cobas ñåðèé 4000-6000-Modular), îñíîâàííûå íà ïðèíöèïå ýëåêòðîõåìèëþìèíåñöåíöèè.
Öèòàòà:
Clin Chim Acta. 2010 Aug 5;411(15-16):1073-9. doi: 10.1016/j.cca.2010.03.041. Epub 2010 Apr 10.
Selected performance characteristics of the Roche Elecsys testosterone II assay on the Modular analytics E 170 analyzer.
Owen WE1, Rawlins ML, Roberts WL.
Author information
Abstract
BACKGROUND:
Serum testosterone measurements have utility in diagnosis of clinical conditions characterized by both increased and decreased testosterone concentrations. Studies have indicated that testosterone immunoassays may give inaccurate results for women and children. We evaluated the performance of a second generation testosterone immunoassay from Roche Diagnostics.
METHODS:
Testo II performed on a Modular Analytics E 170 analyzer is an automated random access electrochemiluminometric assay. We evaluated limit of blank (LoB), imprecision, linearity, interference, and method comparison with liquid chromatography-tandem mass spectrometry assay (LC-MS/MS). Method comparison included the current generation Roche testosterone assay (Testo I) and the Access 2 testosterone chemiluminometric assay (Beckman Coulter). Results for men and women were analyzed for analytic concordance. The relative % differences of immunoassay compared to LC-MS/MS results were evaluated.
RESULTS:
The LoB was 0.07nmol/l. Total imprecision was <6%. The assay was linear from 0.2 to 46.6nmol/l. Negative interference was observed for lipemia at concentrations >22.5g/l. Analytic concordance showed improved specificity for women. Comparison of results to LC-MS/MS indicated comparable performance with other immunoassays for men and improved performance for women, boys, and girls with mean differences of 0.5%, -0.7%, and 24.4%, respectively.
CONCLUSIONS:
The Roche Testo II assay demonstrated excellent precision. Comparison to 2 other automated immunoassays showed comparable performance for men and improved performance for women and children. However, challenges still exist for quantifying testosterone concentrations <10.4nmol/l for men and <1.7nmol/l for women and children by immunoassay.

Êîììåíòàðèè ê ñîîáùåíèþ:
Samitin îäîáðèë(à): Òî÷íî, îøèáñÿ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #10  
Ñòàðûé 07.06.2016, 07:41
Samitin Samitin âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 27.08.2009
Ãîðîä: Ñàðàòîâ
Ñîîáùåíèé: 2,224
Ñêàçàë(à) ñïàñèáî: 8
Ïîáëàãîäàðèëè 765 ðàç(à) çà 691 ñîîáùåíèé
Samitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSamitin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò AlexT Ïîñìîòðåòü ñîîáùåíèå
Íå íóæíî ñìåøèâàòü ðåôåðåíòíûå âåëè÷èíû , ïîëó÷åííûå êàê 95% ÄÈ äëÿ ðàñïðåäåëåíèÿ òåñòîñòåðîíà ðåôåðåíòíîé ïîïóëÿöèè (êàê â ýòîé òåñò-ñèñòåìå) è êëèíè÷åñêèå ïîðîãè ïðèíÿòèÿ ðåøåíèé...
Òàêîãî çäåñü, êàæåòñÿ, íèêòî è íå ïðåäëàãàë...
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò


Îïöèè òåìû Ïîèñê â ýòîé òåìå
Ïîèñê â ýòîé òåìå:

Ðàñøèðåííûé ïîèñê
Îïöèè ïðîñìîòðà

Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 17:10.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.